Swiss Re: pharmaceutical and care-home sectors could provide capacity for longevity swaps

Swiss Re: pharmaceutical and care-home sectors could provide capacity for longevity swaps


The pharmaceutical and care-home industries could be suitable counterparties for longevity swaps, Swiss Re has suggested.

With concerns over whether reinsurers can provide sufficient long-term capacity for longevity risks, Swiss Re argues that these sectors could provide a “natural hedge”.

Daniel Ryan, head of life and health research at Swiss Re, suggests the nature of both industries means they could benefit from increasing longevity, making them ideal counterparties for longevity swap deals.

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact or view our subscription options here:

You are currently unable to copy this content. Please contact to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to View our subscription options


Want to know what’s included in our free membership? Click here

This address will be used to create your account

The future of life insurance

As the world constantly evolves and changes, so too does the life insurance industry, which is preparing for a multitude of challenges, particularly in three areas: interest rates, regulatory mandates and technology (software, underwriting tools and…

You need to sign in to use this feature. If you don’t have a account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here